Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.13M
EBITDA Margin
-6.76%
TTM Avg
-0.42%
3Y Avg
7.09%
5Y Avg
7.09%
Market Cap
$1.17M
EBITDA Margin
-17.60%
TTM Avg
-16.25%
3Y Avg
-23.94%
5Y Avg
-32.10%
Market Cap
$1.01M
EBITDA Margin
-182712.72%
TTM Avg
-182712.72%
3Y Avg
-182712.72%
5Y Avg
-182712.72%
Market Cap
$946332.00
EBITDA Margin
-11.42%
TTM Avg
-13.72%
3Y Avg
-61.43%
5Y Avg
-349.42%
Market Cap
$901902.00
EBITDA Margin
1710.10%
TTM Avg
8440.35%
3Y Avg
4905.18%
5Y Avg
4832.78%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | $1.12M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.13M | -6.76% | -0.42% | 7.09% | 7.09% |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | -17.60% | -16.25% | -23.94% | -32.10% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | -182712.72% | -182712.72% | -182712.72% | -182712.72% |
| Sunshine Biopharma, Inc. (SBFM)vs › | $946332.00 | -11.42% | -13.72% | -61.43% | -349.42% |
| Genprex, Inc. (GNPX)vs › | $1.32M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.33M | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | 1710.10% | 8440.35% | 4905.18% | 4832.78% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.34M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
